How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

[Profile] Daniela Hozbor—raising the bar for pertussis vaccines

After a week of rumors, Makary officially out as FDA head

Quick takes: Pandemic flu preparedness, multiple-pathogen dashboard, more measles in Utah

The State of US Vaccine Policy — May 14, 2026

Quick takes: Another hantavirus case, polio in 3 countries, NIAID head steps down

Anti-HIV CAR-T Cell Therapy Shows Promise in Phase 1/2a Data

HHS Rescinds its New ACIP Charter Plan

Rising Threat of Metallo-Beta-Lactamases Drives Demand for Novel Therapeutics

Preclinical Models Provide Critical Foundation for Antibiotic PK/PD Targets

Advocating for Personalized OPAT Monitoring to Improve Patient Care

Schedule an Appointment

Quick Links

Patient Forms

Contact Us